>>LifeSci Advisors Publishes JAKAFI Survey Results
Last update: 1/24/2012 11:42:00 AM
--Survey Predicts Peak US Sales from $600-$700 million for JAKAFI --Full Results Available for Free Download at lifesciadvisors.com
NEW YORK, Jan. 24, 2012 /PRNewswire via COMTEX/ -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 59 hematologists regarding their current and expected use of JAKAFI (ruxolitinib). JAKAFI is a selective Janus kinase 1 (JAK1) and JAK2 inhibitor developed and marketed in the US by Incyte Corporation and internationally by Novartis. The FDA approved the drug in November 2011 as a treatment for myelofibrosis (MF).
"Based on the results of our proprietary survey we believe that there are approximately 16,200 MF patients currently being treated in the US in academic/major referral and community practices," said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. "Overall, academic and community hematologists expect to treat 45% and 42.4% of the MF patients with JAKAFI, respectively. The survey suggests that JAKAFI should achieve peak sales between $600 and $700 million in the United States."
Dr. McDonald's full Survey Report is available to download at no cost at the LifeSci Advisors website.<<
snip
Free registration required.
Cheers, Tuck |
